neurotoxins

Evolus Expands Leadership Team

Evolus, a company dedicated to aesthetic medicine that is currently developing its own botulinum toxin injectable, has expanded its leadership team with the appointments of three key executives, who will report to President and CEO David Moatazedi. Kurt Knab is the vice president of sales, Alejandro “Alex” Sabad is vice president of operations and Amy Marinne Fox is vice president of human resources.

Allergan to Acquire Bonti

Allergan has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development: EB-001A (aesthetic) and EB-001T (therapeutic).

Global Injections

Full-face rejuvenation with injectables offers high patient satisfaction, but requires advanced training and an awareness of risk factors.
MedEsthetics July/August 2018

When medical aesthetic practices first began to use the term “Liquid Facelift” to describe the use of fillers and botulinum toxins for facial rejuvenation, there was some discomfort in the industry. Many practitioners were wary of suggesting that patients could achieve results comparable to a facelift nonsurgically, and the outcomes were not always ideal. But with experience, new indications and improved techniques, outcomes have improved significantly.

Evolus Vows To Move Forward As FDA Fails To Approve Its Neurotoxin

The approval of Evolus’ DWP-450 (prabotulinumtoxinA) has hit a snag, reportedly due to issues at the appointed manufacturing facility. The U.S. Food & Drug Administration issued a complete response letter (CRL) to the company’s biologic license application for DWP-450 outlining concerns that must be addressed before the FDA can approve the new neurotoxin for marketing in the U.S.

No Pain, Swift Gains

A new neurotoxin with a fast onset of action and shorter duration of effect is in development for aesthetics and pain relief.
Botulinum toxin with faster onset of action on horizon

While the aesthetics industry has been focused on new botulinum toxin products and dosing strategies geared toward increasing longevity of results, a new company Bonti has been developing EB-001, a serotype E botulinum toxin that moves in the opposite direction. “This molecule is very similar to the existing botulinum toxin serotype A products in terms of mechanism of action, however, it has two differentiating factors.

Comparing Three Botulinum Toxins

Comparing Three Botulinum Toxins

A study in Plastic and Reconstructive Surgery (May 2016) used digital image correlation to compare dynamic strain reduction between three U.S. Food and Drug Administration (FDA)-approved formulations of botulinum toxin: onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) and incobotulinumtoxinA (Xeomin, Merz).

Injecting Men

Understanding the unique anatomical characteristics of the male face is key to providing the best aesthetic outcomes with fillers and neurotoxins.
Injecting Men

An angular jaw with a prominent chin, eyes framed by a smattering of smile lines and a full brow—the male aesthetic ideal is distinctly different than the soft curves, arched brow and high cheekbones sought by female patients. Yet men do share the same desire as women to put their best faces forward, and by understanding their unique anatomical attributes you can use your existing range of injectables to deliver the subtle improvements they are seeking from their aesthetic providers.